Literature DB >> 7036292

Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results.

P Schlag, W Schreml, W Gaus, C Herfarth, M M Linder, W Queisser, M Trede.   

Abstract

One hundred-three patients with a potentially curative operation of a histologically proven gastric cancer were randomly assigned to a control and chemotherapy group after stratification according to tumor stage II and III. Chemotherapy courses with 5-fluorouracil (10 mg/kg/day) and BCNU (40 mg/m2/day) for 5 days were administered eight times in 6-8 week intervals. Age, sex, and tumor location were matched in the chemotherapy and control groups. Five patients declined treatment after randomization. Three years after initiating the study, the tumor has recurred in 38 of the 103 patients. There were 21 recurrences of 54 controls and 14 recurrences of 44 patients who received chemotherapy, and 17 and ten deaths, respectively, due to tumor relapse. The results of our study to data show a high degree of statistical probability that adjuvant chemotherapy with the regime used has no influence on the recurrence-free interval and survival time in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7036292     DOI: 10.1007/978-3-642-81685-7_44

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  2 in total

1.  Adjuvant chemotherapy in gastric cancer.

Authors:  P Schlag
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

2.  Survival Benefit of Three Different Therapies in Postoperative Patients With Advanced Gastric Cancer: A Network Meta-Analysis.

Authors:  Dong-Mei Wu; Shan Wang; Xin Wen; Xin-Rui Han; Yong-Jian Wang; Min Shen; Shao-Hua Fan; Zi-Feng Zhang; Juan Zhuang; Qun Shan; Meng-Qiu Li; Bin Hu; Chun-Hui Sun; Jun Lu; Yuan-Lin Zheng
Journal:  Front Pharmacol       Date:  2018-08-22       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.